The DOI matches its Crossref record, with a small difference in title or year; 66 of the 67 references it cites were found in a registry or an index.
Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy
Abstract
Obesity is a worldwide problem, with major health, social and economic implications. The adaptation of drug dosages to obese patients is a subject of concern, particularly for drugs with a narrow therapeutic index. The main factors that affect the tissue distribution of drugs are body composition, regional blood flow and the affinity of the drug for plasma proteins and/or tissue components. Obese people have larger absolute lean body masses as well as fat masses than non-obese individuals of the same age, gender and height. However, the percentage of fat per kg of total bodyweight (TBW) is markedly increased, whereas that chrome P450 isoforms are altered, but no clear overview of drug hepatic metabolism in obesity is currently available. Pharmacokinetic studies provide differing data on renal function in obese patients. This review analyses recent publications on several classes of drugs: antibacterials, anticancer drugs, psychotropic drugs, anticonvulsants, general anaesthetics, opioid analgesics, neuromuscular blockers, beta-blockers and drugs commonly used in the management of obesity. Pharmacokinetic studies in obesity show that the behaviour of molecules with weak or moderate lipophilicity (e.g. lithium and vecuronium) is generally rather predictable, as these drugs are distributed mainly in lean tissues. The dosage of these drugs should be based on the ideal bodyweight (IBW). However, some of these drugs (e.g. antibacterials and some anticancer drugs) are partly distributed in adipose tissues, and their dosage is based on IBW plus a percentage of the patient's excess bodyweight. There is no systematic relationship between the degree of lipophilicity of markedly lipophilic drugs (e.g. remifentanil and some beta-blockers) and their distribution in obese individuals. The distribution of a drug between fat and lean tissues may influence its pharmacokinetics in obese patients. Thus, the loading dose should be adjusted to the TBW or IBW, according to data from studies carried out in obese individuals. Adjustment of the maintenance dosage depends on the observed modifications in clearance. Our present knowledge of the influence of obesity on drug pharmacokinetics is limited. Drugs with a small therapeutic index should be used prudently and the dosage adjusted with the help of drug plasma concentrations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, often little systematic relationship exists between the degree of lipophilicity of markedly lipophilic drugs and their distribution in individuals with obesity.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [23]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Pharmacokinetics and Pharmacodynamics of Remifentanil: II. Model Application
Minto, C. F., Schnider, T. W., & Shafer, S. L. (1997) · Anesthesiology · doi:10.1097/00000542-199701000-00005 · Cited by 682
Bernard, Testa, M., Meyer, U., & Testa, B. (1964) · Academic Press eBooks · Cited by 609
The pharmacokinetics of Norpace.
Karim, A. (1975) · PubMed · Cited by 552
de Divitiis, O., Fazio, S., Petitto, M., Maddalena, G., Contaldo, F., & Mancini, M. (1981) · Circulation · doi:10.1161/01.cir.64.3.477 · Cited by 394
Clinical Pharmacokinetics of Fluoxetine
Altamura, A. C., Moro, A. R., & Percudani, M. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426030-00004 · Cited by 336
Lean Body Mass as a Predictor of Drug Dosage: Implications for Drug Therapy
Morgan, D. J., & Bray, K. M. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426040-00005 · Cited by 299
Servin, F., Farinotti, R., Haberer, J.-P., & Desmonts, J.-M. (1993) · Anesthesiology · doi:10.1097/00000542-199304000-00008 · Cited by 282
Research works printed but not linked: 11
- 1959, ull, 40, 1
- Lehingue, 1996, Rev Epidemiol Sante Publique, 44, 37
- Forbes, 1983, Int J Obesity, 7, 99
- Leader, 1994, Am J Hosp Pharm, 51, 2155
- Bachur, 1979, Cancer Treat Rep, 63, 817
- Schwartz, 1991, Anesth Analg, 73, 790
- Schwartz, 1992, Anesth Analg, 74, 515
- Cheymol, 1995, Br J Clin Pharmacol, 39, 684
- Garratt, 1995, J Clin Pharmacol, 35, 928
- Caraco, 1995, Int J Obes, 19, 234
- Zahorska-Markiewicz, 1996, Int J Clin Pharmacol Ther, 34, 393
Cited by
Quantification of Lean Bodyweight
Janmahasatian, S., Duffull, S. B., Ash, S., Ward, L. C., Byrne, N. M., & Green, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00004 · Cited by 900
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773
Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
Anderson, B. J., & Holford, N. H. G. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.25 · Cited by 494
Dose adjustment of anaesthetics in the morbidly obese
Ingrande, J., & Lemmens, H. J. M. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq312 · Cited by 445
Obesity as a Correlate of Outcome in Patients With Bipolar I Disorder
Fagiolini, A., Kupfer, D. J., Houck, P. R., Novick, D. M., & Frank, E. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.112 · Cited by 405
Metadata
- Authors
- Cheymol, G.
- Corresponding author
- Cheymol, Georges
- Venue
- Clinical Pharmacokinetics
- Published
- 2000-09
- Volume
- 39
- Issue
- 3
- Pages
- 215-231
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2107564745
- Cited by
- 631
- References
- 67
- Citations by year
- 2026: 17 · 2025: 30 · 2024: 22 · 2023: 22 · 2022: 24 · 2021: 31 · 2020: 39 · 2019: 25 · 2018: 22 · 2017: 34 · 2016: 32 · 2015: 26 · 2014: 41 · 2013: 27 · 2012: 45
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- obesity, pharmacokinetics, drug dosing, tissue distribution, body composition, lean body mass, adipose tissue, lipophilicity, ideal body weight, drug clearance, renal function, hepatic metabolism, drug interactions, antibacterial agents, anticancer agents, psychotropic drugs, antiepileptic drugs, general anesthetics, opioid analgesics, neuromuscular blocking agents, beta-blockers, loading dose, therapeutic index
- MeSH terms
- Adrenergic beta-Antagonists, Anesthetics, Anti-Bacterial Agents, Anticonvulsants, Antifungal Agents, Antineoplastic Agents, Humans, Hypoglycemic Agents, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy. https://app.cochat.ai/papers/10.2165/00003088-200039030-00004
- The paper
- Cheymol, G. (2000). Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200039030-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.